Drug interactions between antiretrovirals and drugs used to treat benign prostatic hyperplasia/lower urinary tract symptoms

References

• Joint United Nations Programme on HIV/AIDS (UNAIDS). HIV and aging: a special supplement to the UNAIDS report on the global AIDS epidemic 2013. Geneva: UNAIDS; 2013.
   Google Scholar
• Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013;8(12):e81355.
   PubMed Web of Science ®Google Scholar
• Public Health Agency of Canada. Chapter 6: HIV/AIDS among older Canadians [Internet]. HIV/AIDS Epi Updates - July 2010. [cited 2016 Mar 28]. Available from: http://www.phac-aspc.gc.ca/aids-sida/publication/epi/2010/6-eng.php
   Google Scholar
• Surveillance and Epidemiology Division; Centre for Communicable Diseases and Infection Control; Public Health Agency of Canada. HIV and AIDS in Canada [Internet]. Surveillance report to December 31, 2013. [ cited 2016 Mar 28]. Available from: http://www.catie.ca/en/resources/hiv-and-aids-canada-surveillance-report-december-31-2013
   Google Scholar
• Hughes CA, Tseng A, Cooper R. Managing drug interactions in HIV-infected adults with comorbid illness. CMAJ. 2015 Jan 6;187(1):36–43.
   PubMed Web of Science ®Google Scholar
• Tseng A, Szadkowski L, Walmsley S, et al. Association of age with polypharmacy and risk of drug interactions with antiretroviral medications in HIV-positive patients. Ann Pharmacother. 2013 Nov;47(11):1429–1439.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Veterans Affairs. Urology: primary care of veterans with HIV [Internet]. Benign Prostatic Hypertrophy. [updated 2011 Oct 28; cited 2016 Mar 28]. Available from: http://www.hiv.va.gov/provider/manual-primary-care/urology.asp#S2X
   Google Scholar
• Roehrborn C. Benign prostatic hyperplasia and lower urinary tract symptom guidelines. Can Urol Assoc J. 2012 Oct;6(5 Suppl 2):S130–2.
   PubMedGoogle Scholar
• Roehrborn CG, McConnell JD. Etiology, pathophysiology, epidemiology and natural history of benign prostatic hyperplasia. In: Campbell’s urology. 8th ed. Philadelphia (PA): W.B. Saunders Co; 2001. p. 1297–1336.
   Google Scholar
• Auffenberg GB, Helfand BT, McVary KT. Established medical therapy for benign prostatic hyperplasia. Urol Clin North Am. 2009 Nov;36(4):443–459, v–vi.
   PubMed Web of Science ®Google Scholar
• Kapoor A. Benign prostatic hyperplasia (BPH) management in the primary care setting. Can J Urol. 2012 Oct;19(Suppl 1):10–17.
   PubMed Web of Science ®Google Scholar
• McConnell JD, Bruskewitz R, Walsh P, et al. The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med. 1998 Feb 26;338(9):557–563.
   PubMed Web of Science ®Google Scholar
• McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011 May;185(5):1793–1803.
   PubMed Web of Science ®Google Scholar
• Gupta K, Yezdani M, Sotelo T, et al. A synopsis of drugs currently in preclinical and early clinical development for the treatment of benign prostatic hyperplasia. Expert Opin Investig Drugs. 2015;24(8):1059–1073.
   PubMed Web of Science ®Google Scholar
• Canadian Pharmacists Association (CPhA). Alpha1-adrenergic Receptor Antagonists (alfuzosin HCl—doxazosin mesylate—prazosin HCl—silodosin—tamsulosin HCl—terazosin HCl) CPhA Monograph. Ottawa (ON): Canadian Pharmacists Association; 2015 Jun.
   Google Scholar
• Irani J. Are all alpha-blockers created the same? Eur Urol. 2006 Mar;49(3):420–422.
   PubMed Web of Science ®Google Scholar
• Oelke M, Bachmann A, Descazeaud A, et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol. 2013 Jul;64(1):118–140.
   PubMed Web of Science ®Google Scholar
• Oelke M, Gericke A, Michel MC. Cardiovascular and ocular safety of alpha1-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms. Expert Opin Drug Saf. 2014 Sep;13(9):1187–1197.
   PubMed Web of Science ®Google Scholar
• Schwinn DA, Michelotti GA. Alpha1-adrenergic receptors in the lower urinary tract and vascular bed: potential role for the alpha1d subtype in filling symptoms and effects of ageing on vascular expression. BJU Int. 2000 Apr;85(Suppl 2):6–11.
   PubMed Web of Science ®Google Scholar
• Hatano A, Takahashi H, Tamaki M, et al. Pharmacological evidence of distinct alpha 1-adrenoceptor subtypes mediating the contraction of human prostatic urethra and peripheral artery. Br J Pharmacol. 1994 Nov;113(3):723–728.
   PubMed Web of Science ®Google Scholar
• Nickel JC, Sander S, Moon TD. A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract. 2008 Oct;62(10):1547–1559.
   PubMed Web of Science ®Google Scholar
• Elhilali MM. Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Expert Opin Pharmacother. 2006 Apr;7(5):583–596.
   PubMed Web of Science ®Google Scholar
• Osman NI, Chapple CR, Cruz F, et al. Silodosin: a new subtype selective alpha-1 antagonist for the treatment of lower urinary tract symptoms in patients with benign prostatic hyperplasia. Expert Opin Pharmacother. 2012 Oct;13(14):2085–2096.
   PubMed Web of Science ®Google Scholar
• Tatemichi S, Kobayashi K, Maezawa A, et al. Alpha1-adrenoceptor subtype selectivity and organ specificity of silodosin (KMD-3213). Yakugaku Zasshi. 2006 Mar;126:209–216.
   PubMed Web of Science ®Google Scholar
• Capitanio U, Salonia A, Briganti A, et al. Silodosin in the management of lower urinary tract symptoms as a result of benign prostatic hyperplasia: who are the best candidates. Int J Clin Pract. 2013 Jun;67(6):544–551.
   PubMed Web of Science ®Google Scholar
• Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology. 1998 Jun;51(6):892–900.
   PubMed Web of Science ®Google Scholar
• Osman NI, Chapple CR, Tammela TL, et al. Open-label, 9-month extension study investigating the uro-selective alpha-blocker silodosin in men with LUTS associated with BPH. World J Urol. 2015 May;33(5):697–706.
   PubMed Web of Science ®Google Scholar
• Masumori N. Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia. Ther Clin Risk Manag. 2011;7:227–238.
   PubMed Web of Science ®Google Scholar
• Takei R, Ikegaki I, Shibata K, et al. Naftopidil, a novel alpha1-adrenoceptor antagonist, displays selective inhibition of canine prostatic pressure and high affinity binding to cloned human alpha1-adrenoceptors. Jpn J Pharmacol. 1999 Apr;79(4):447–454.
   PubMedGoogle Scholar
• McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003 Dec 18;349(25):2387–2398.
   PubMed Web of Science ®Google Scholar
• Clark RV, Hermann DJ, Gabriel H, et al. Effective suppression of dihydrotestosterone (DHT) by GI198745, a novel dual 5 alpha-reductase inhibitor [abstract 1037]. J Urol. 1999;161:268.
   Google Scholar
• McConnell JD, Wilson JD, George FW, et al. Finasteride, an inhibitor of 5 alpha-reductase, suppresses prostatic dihydrotestosterone in men with benign prostatic hyperplasia. J Clin Endocrinol Metab. 1992 Mar;74(3):505–508.
   PubMed Web of Science ®Google Scholar
• Gacci M, Carini M, Salvi M, et al. Management of benign prostatic hyperplasia: role of phosphodiesterase-5 inhibitors. Drugs Aging. 2014 Jun;31(6):425–439.
   PubMed Web of Science ®Google Scholar
• Eli Lilly Canada Inc. Cialis® (tadalafil) Product Monograph. Toronto (ON): Eli Lilly Canada Inc; 2015 Jan 23.
   Google Scholar
• Carson CC, Rosenberg M, Kissel J, et al. Tadalafil – a therapeutic option in the management of BPH-LUTS. Int J Clin Pract. 2014 Jan;68(1):94–103.
   PubMed Web of Science ®Google Scholar
• Morelli A, Sarchielli E, Comeglio P, et al. Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med. 2011 Oct;8(10):2746–2760.
   PubMed Web of Science ®Google Scholar
• Pfizer Canada Inc. Cardura® (doxazosin) product monograph. Kirkland (QC): Pfizer Canada Inc; 2012 Sep 18.
   Google Scholar
• Kaye B, Cussans NJ, Faulkner JK, et al. The metabolism and kinetics of doxazosin in man, mouse, rat and dog. Br J Clin Pharmacol. 1986;21(Suppl 1):19S–25S.
   PubMedGoogle Scholar
• Abbott Laboratories, Limited. Hytrin® (terazosin) product monograph. St. Laurent (QC): Abbott Laboratories, Limited; 2010 Dec 13.
   Google Scholar
• Oh EY, Bae SK, Kwon JW, et al. Pharmacokinetic and pharmacodynamic consequences of inhibition of terazosin metabolism via CYP3A1 and/or 3A2 by DA-8159, an erectogenic, in rats. Br J Pharmacol. 2007 May;151(1):24–34.
   PubMed Web of Science ®Google Scholar
• Sanofi-Aventis Canada Inc. Xaltral® (alfuzosin) Product Monograph. Laval (QC): Sanofi-Aventis Canada Inc; 2014 Jul 3.
   Google Scholar
• Buzelin JM, Delauche-Cavallier MC, Roth S, et al. Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction. Br J Urol. 1997 Jun;79(6):898–904; discussion 04–6.
   PubMedGoogle Scholar
• Boehringer Ingelheim (Canada) Ltd. Flomax® CR (tamsulosin) product monograph. Burlington (ON): Boehringer Ingelheim (Canada) Ltd; 2014 Feb 21.
   Google Scholar
• Boehringer Ingelheim Pharmaceuticals Inc. Flomax® (tamsulosin hydrochloride, USP) prescribing information. Ridgefield (CT): Boehringer Ingelheim Pharmaceuticals Inc; 2016 Jan.
   Google Scholar
• Watson Laboratories Inc. Rapaflo® (silodosin) product monograph. Salt Lake City (UT): Watson Laboratories Inc; 2013 Jun 10.
   Google Scholar
• GlaxoSmithKline Inc. Avodart® (dutasteride) product monograph. Mississauga (ON): GlaxoSmithKline Inc; 2013 Sep 12.
   Google Scholar
• Merck Canada Inc. Proscar® (finasteride) product monograph. Kirkland (QC): Merck Canada Inc; 2014 Mar 19.
   Google Scholar
• Ishii Y, Mukoyama H, Ohtawa M. In vitro biotransformation of finasteride in rat hepatic microsomes. Isolation and characterization of metabolites. Drug Metab Dispos. 1994 Jan–Feb;22(1):79–84.
   PubMed Web of Science ®Google Scholar
• Soeishi Y, Matsushima H, Watanabe T, et al. Absorption, metabolism and excretion of tamsulosin hydrochloride in man. Xenobiotica. 1996;26:637–645.
   PubMed Web of Science ®Google Scholar
• Kamimura HOS, Matsushima H, Watanabe T, et al. Identification of cytochrome P450 isozymes involved in metabolism of the a1-adrenoceptor blocker tamsulosin in human liver microsomes. Xenobiotica. 1998;28:909–922.
   PubMed Web of Science ®Google Scholar
• Taguchi K, Saitoh M, Sato S, et al. Effects of tamsulosin metabolites at alpha-1 adrenoceptor subtypes. J Pharmacol Exp Ther. 1997;280:1–5.
   PubMed Web of Science ®Google Scholar
• Huskey SW, Dean DC, Miller RR, et al. Identification of human cytochrome P450 isozymes responsible for the in vitro oxidative metabolism of finasteride. Drug Metab Dispos. 1995 Oct;23(10):1126–1135.
   PubMed Web of Science ®Google Scholar
• Eli Lilly Canada. Adcirca® (tadalafil) product monograph. Toronto (ON): Eli Lilly Canada Inc; 2015 Jan 26.
   Google Scholar
• Pfizer Canada Inc. Viagra (sildenafil) product monograph. Kirkland (QC): Pfizer Canada Inc; 2015 May 26.
   Google Scholar
• Bayer Inc. Levitra® (vardenafil) product monograph. Mississauga (ON): Bayer Inc; 2015 Jun 4.
   Google Scholar
• Lee HS, Park EJ, Ji HY, et al. Identification of cytochrome P450 enzymes responsible for N -dealkylation of a new oral erectogenic, mirodenafil. Xenobiotica. 2008 Jan;38(1):21–33.
   PubMed Web of Science ®Google Scholar
• Lee J, Yoo HH, Rhim KJ, et al. Metabolism and excretion of 5-ethyl-2-{5-[4-(2-hydroxyethyl)piperazine-1-sulfonyl]-2-propoxyphenyl}-7-propyl- 3,5-dihydropyrrolo[3,2-d]-pyrimidin-4-one (SK3530) in rats. Rapid Commun Mass Spectrom. 2007;21(7):1139–1149.
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and Adolescents. Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents; [updated 2016 Jan 28; cited 2016 Mar 28]. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf.
   Google Scholar
• Boehringer Ingelheim (Canada) Ltd. Aptivus® (tipranavir) product monograph. Burlington (ON): Boehringer Ingelheim (Canada) Ltd; 2014 Mar 5.
   Google Scholar
• AbbVie Corporation. Kaletra® (lopinavir/ritonavir) product monograph. St. Laurent (QC): AbbVie Corporation; 2015 Nov 17.
   Google Scholar
• AbbVie Corporation. Norvir® (ritonavir) product monograph. St. Laurent (QC): AbbVie Corporation; 2015 May 7.
   Google Scholar
• Hesse LM, Von Moltke LL, Shader RI, et al. Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metab Dispos. 2001 Feb;29(2):100–102.
   PubMed Web of Science ®Google Scholar
• Kharasch ED, Mitchell D, Coles R, et al. Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. Antimicrob Agents Chemother. 2008;52(5):1663–1669.
   PubMed Web of Science ®Google Scholar
• Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother. 2008 Jul;42(7):1048–1059.
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb Canada. Sustiva® (efavirenz) product monograph. Montreal (QC): Bristol-Myers Squibb Canada; 2015 Jun 19.
   Google Scholar
• Janssen Inc. Intelence® (etravirine) product monograph. Toronto (ON): Janssen Inc; 2014 Aug 14.
   Google Scholar
• Boehringer Ingelheim (Canada) Ltd. Viramune® and Viramune XR® (nevirapine) product monograph. Burlington (ON): Boehringer Ingelheim (Canada) Ltd; 2013 Nov 18.
   Google Scholar
• Merck Canada Inc. Isentress® (raltegravir) product monograph. Kirkland (QC): Merck Canada Inc; 2015 Jan 20.
   Google Scholar
• ViiV Healthcare ULC. Tivicay™ (dolutegravir) product monograph. Laval (QC): ViiV Healthcare ULC; 2014 Mar 11.
   Google Scholar
• Kassahun K, McIntosh I, Cui D, et al. Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 integrase enzyme. Drug Metab Dispos. 2007 Sep;35(9):1657–1663.
   PubMed Web of Science ®Google Scholar
• Gilead Sciences Canada Inc. Stribild® (elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil fumarate) product monograph. Mississauga (ON): Gilead Sciences Canada Inc; 2015 Nov 20.
   Google Scholar
• Gilead Sciences Canada Inc. Tybost™ (cobicistat) product monograph. Mississauga (ON): Gilead Sciences Canada Inc; 2013 Aug 23.
   Google Scholar
• Bristol-Myers Squibb Canada. Reyataz™ (atazanavir) product monograph. Montreal (QC): Bristol-Myers Squibb Canada; 2013 Sep 25.
   Google Scholar
• Janssen Inc. Prezista® (darunavir) product monograph. Toronto (ON): Janssen Inc; 2014 Sep 18.
   Google Scholar
• ViiV Healthcare ULC. Telzir® (fosamprenavir) product monograph. Laval (QC): ViiV Healthcare ULC; 2016 Jan 5.
   Google Scholar
• Merck Canada Inc. Crixivan® (indinavir) product monograph. Kirkland (QC): Merck Canada Inc; 2015 Oct 29.
   Google Scholar
• Pfizer Canada Inc. Viracept® (nelfinavir) product monograph. Kirkland (QC): Pfizer Canada Inc; 2012 Dec 21.
   Google Scholar
• Dixit V, Hariparsad N, Li F, et al. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos. 2007 Oct;35(10):1853–1859.
   PubMed Web of Science ®Google Scholar
• Hoffmann-La Roche Limited. Invirase® (saquinavir) product monograph. Mississauga (ON): Hoffmann-La Roche Limited; 2015 Dec 9.
   Google Scholar
• Vourvahis M, Dumond J, Patterson K, et al. Effects of tipranavir/ritonavir on the activity of cytochrome p450 enzymes 1A2, 2C9 and 2D6 in healthy volunteers. 8th International Workshop on Clinical Pharmacology of HIV Therapy; 2007 Apr 16–18; Budapest, Hungary.
   Google Scholar
• Anderson MS, Gilmartin J, Cilissen C, et al. Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects. Antivir Ther. 2015;20(4):397–405.
   PubMed Web of Science ®Google Scholar
• Robertson SM, Maldarelli F, Natarajan V, et al. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. J Acquir Immune Defic Syndr. 2008 Dec 15;49(5):513–519.
   PubMed Web of Science ®Google Scholar
• Lee L, Soon GH, Shen P, et al. Effect of efavirenz and darunavir/ritonavir on bilirubin levels in healthy adult volunteers: role of induction of UGT1A1 and bile efflux transporters. 11th International Workshop on Clinical Pharmacology of HIV Therapy; 2010 Apr 5–7; Sorrento, Italy.
   Google Scholar
• Janssen Inc. Edurant® (rilpivirine) product monograph. Toronto (ON): Janssen Inc; 2014 Aug 13.
   Google Scholar
• Crauwels HM, Van Heeswijk R, Stevens T, et al. The effect of TMC278, a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) on CYP3A activity in vivo. 10th International Workshop on Clinical Pharmacology of HIV Therapy; 2009 Apr 15–17; Amsterdam, The Netherlands.
   Google Scholar
• Lenz ML, Pool JL, Laddu AR, et al. Combined terazosin and verapamil therapy in essential hypertension. Hemodynamic and pharmacokinetic interactions. Am J Hypertens. 1995 Feb;8(2):133–145.
   PubMed Web of Science ®Google Scholar
• Guay DR. Extended-release alfuzosin hydrochloride: a new alpha-adrenergic receptor antagonist for symptomatic benign prostatic hyperplasia. Am J Geriatr Pharmacother. 2004 Mar;2(1):14–23.
   PubMedGoogle Scholar
• Troost J, Tatami S, Tsuda Y, et al. Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin. Br J Clin Pharmacol. 2011 Aug;72(2):247–256.
   PubMed Web of Science ®Google Scholar
• Garraffo R, Lavrut T, Ferrando S, et al. Effect of tipranavir/ritonavir combination on the pharmacokinetics of tadalafil in healthy volunteers. J Clin Pharmacol. 2011 Jul;51(7):1071–1078.
   PubMed Web of Science ®Google Scholar
• Loulergue P, Gaillard R, Mir O. Interaction involving tadalafil and CYP3A4 inhibition by ritonavir. Scand J Infect Dis. 2011 Mar;43(3):239–240.
   PubMed Web of Science ®Google Scholar
• Sekar V, Lefebvre E, De Marez T, et al. Effect of repeated doses of darunavir plus low-dose ritonavir on the pharmacokinetics of sildenafil in healthy male subjects: phase I randomized, open-label, two-way crossover study. Clin Drug Investig. 2008;28(8):479–485.
   PubMed Web of Science ®Google Scholar
• Merry C, Barry MG, Ryan M, et al. Interaction of sildenafil and indinavir when co-administered to HIV-positive patients. Aids. 1999 Oct 22;13(15):F101–7.
   PubMed Web of Science ®Google Scholar
• Muirhead GJ, Wulff MB, Fielding A, et al. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir. Br J Clin Pharmacol. 2000 Aug;50(2):99–107.
   PubMed Web of Science ®Google Scholar
• Schöller-Gyüre M, Debroye C, Vyncke C Effect of TMC125 on sildenafil pharmacokinetics. 7th International Workshop on Clinical Pharmacology of HIV Therapy; 2006 Apr 20–22; Lisbon, Portugal.
   Google Scholar
• Kakuda TN, Schöller-Gyüre M, Woodfall BJ, et al. TMC125 in combination with other medications: summary of drug-drug interactions. 8th International Congress on Drug Therapy in HIV Infection; 2006 Nov 12–16; Glasgow, Scotland.
   Google Scholar
• Crauwels HM, Van Heeswijk R, Stevens M, et al. TMC278, a next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI), does not alter the pharmacokinetics of sildenafil. 10th International Workshop on Clinical Pharmacology of HIV Therapy; 2009 Apr 15–17; Amsterdam, The Netherlands.
   Google Scholar
• Kakuda TN, Kiser JJ. 7th International Workshop on Clinical Pharmacology of HIV Therapy 20-22 April 2006, Lisbon, Portugal. Expert Opin Pharmacother. 2006 Aug;7(11):1519–1533.
   PubMed Web of Science ®Google Scholar
• Shin KH, Kim BH, Kim TE, et al. The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study. Clin Ther. 2009 Dec;31(12):3009–3020.
   PubMed Web of Science ®Google Scholar
• Santi D, Brigante G, Zona S, et al. Male sexual dysfunction and HIV–a clinical perspective. Nat Rev Urol. 2014 Feb;11(2):99–109.
   PubMed Web of Science ®Google Scholar
• Health Canada. Summary basis of decision. Rapaflo.Silodosin, 8 mg and 4 mg capsules. Watson Laboratories. Submission Control Number: 121740; 2011.
   Google Scholar